Cardiac effects of psychedelic drugs

致幻药物对心脏的影响

• 批准号: 510383218
• 负责人: Professor Dr. Joachim Neumann
• 金额: --
• 依托单位: Institut für Pharmakologie und Toxikologie
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2022
• 资助国家: 德国
• 起止时间: 2021-12-31 至 2023-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/510383218?language=en
• 关键词: Cardiac; effects; psychedelic; drugs

Some hallucinogens like psilocin, psilocybin, dimethyltryptamine, and 5-methoxy-dimethyltryptamine are under discussion as therapeutic drugs to treat some kinds of depression. Here, we want to know if these hallucinogens have any cardiac effects and if they act positive inotropic and positive chronotropic via serotonin 5-HT4 receptors. To that end, we use a transgenic mouse model with heart specific overexpression of human 5-HT4 receptors that has been developed and characterized by ourselves. Moreover, the signal transduction of the cardiac effects of these hallucinogens should be identified in more detail. The project should help to increase the safety of drug therapies and to improve the treatment of overdosage.

一些致幻剂如裸盖菇素、裸盖菇素、二甲基色胺和5-甲氧基二甲基色胺正在讨论作为治疗药物来治疗某些类型的抑郁症。在这里，我们想知道这些致幻剂是否有任何心脏作用，以及它们是否通过5-羟色胺5-HT 4受体发挥正性肌力和正性变时作用。为此，我们使用了一个转基因小鼠模型与心脏特异性过表达的人5-HT 4受体，已开发和表征自己。此外，这些致幻剂的心脏效应的信号转导应更详细地确定。该项目应有助于提高药物治疗的安全性，并改善对药物过量的治疗。